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Chronic Myeloid Leukemia
Efficacy of imatinib mesylate as maintenance
therapy in adults with acute lymphoblastic
leukemia in first complete remission
Seven Philadelphia chromosome-positive acute
lymphoblastic leukemia (Ph+ALL) patients in first
complete remission received maintenance therapy
with imatinib alone. Two-year progression-free
survival was 75%. Quantitative polymerase-chain-
reaction (qPCR) monitoring of BCR-ABL showed
that: (i) persisting molecular complete response
(CR) was associated with long-lasting CR; (ii)
molecular relapse did not invariably mean hemato-
logic relapse; (iii) only the wide and rapid incre-
ment of BCR-ABL values was predictive of
leukemia relapse. haematologica 2005; 90:1275-1277
(http://www.haematologica.org/journal/2005/9/1275.html)
Imatinib mesylate has been shown to induce remis-
sions in more than two-thirds of patients with
relapsed/refractory Philadelphia chromosome positive
acute lymphoblastic leukemia (Ph+ALL), although for
short time. Serial quantitative reverse-transcriptase poly-
merase-chain-reaction (qRT-PCR) monitoring of BCR-
ABL has shown utility in predicting leukemia relapse and
bridging the time to bone marrow transplantation
(BMT).1-5 We evaluated the efficacy of imatinib alone for
long-term maintenance therapy in seven consecutive
Ph+ALL patients in first hematologic complete remission
(hCR), and the usefulness of a strict minimal residual dis-
ease (MRD) follow-up to identify patients who may ben-
efit from prolonged imatinib maintenance. 
Table 1A summarizes the clinical characteristics of the
seven patients. At diagnosis, karyotypic analysis showed
the t(9;22) translocation in all patients, and revealed addi-
tional chromosomal alterations in three (43%) out of the
seven patients, namely +14, del(10q) and del(20). In five
patients induction treatment was a multiagent chemother-
apy regimen, detailed in Table 1A. The other two patients,
older than 65 years, received prednisone 40 mg/m2 daily
and imatinib 800 mg/day for 30 days as induction treat-
ment. At the end of induction, all patients were in com-
plete remission (CR) and received maintenance treatment
with imatinib 800 mg/day until toxicity or leukemia
relapse (Table 1A). MRD monitoring was performed on
bone marrow aspirates collected at admission, at the end
of induction treatment and then, monthly, during the
maintenance therapy. Molecular CR (mCR) was defined as
described by Gabert et al.6 The definition of hCR and the
algorithms for MRD evaluation were drawn from
Scheuring et al.3 and were modified as follows: minimum
BCR-ABL level: the lowest measured relative BCR-ABL
level prior to an increase or identical value; increased BCR-
ABL level: the highest value after the minimum (it was con-
sidered if the sample was obtained at least 15 days prior to
hematologic relapse [hRel]; magnitude of increase: the log
ratio between the increased BCR-ABL and the minimum, as
defined above; persisting mCR: mCR sustained for at least
three months and short mCR: mCR detected in a single
observation or sustained for less than three months.
Kaplan-Meier curves and the hazard rate were calculated
using STATA (release 8) software. Overall survival (OS)
and progression-free survival (PFS) are shown in Figures
1A and B. The hazard rate was 0.00021617. Six out of
seven patients (86%) were still in hCR at a median follow-
Table 1 A. Characteristics of patients at baseline and their treat-
ment outcome.
Characteristics Patients
Median age, y (range) 59 (34-79)
Sex, no (%)
Male 3 (43)
Female 4 (57)
Subtype of ALL, no. (%)
c-ALL 5 (72)
Pre-B-ALL 1(14)
Pro-B-ALL 1(14)
p190Bcr-Abl vs p210Bcr-Abl, no. (%)
m-Bcr-Abl 4 (57)
M- Bcr-Abl 3 (43)
Karyotype, no. (%)
Additional cytogenetics abnormalities 3 (43)
t(9;22) 7 (100)
CNS leukemia, no. (%) 0 (0%)
Induction chemotherapy regimen, no. (%)
DNM+VCR+ PDN for 30 days 5 (71)
PDN 40 mg+Imatinib 800 mg/day 
for 30 days 2*(29)
Outcome of Induction
hCR 7 (100)
Consolidation/maintenance regimen, no. (%)
Imatinib 800 mg/day 7 (100%)
CNS Prophylaxis
during induction and maintenance
MTX i.t. 15 mg/monthly for 16 months 7 (100%)
DNM: daunorubicin; PDN: prednisone; VCR: vincristine; MTX: methotrexate;
hCR: hematologic complete remission. *Two patients over 65 years old.
Table 1B. BCR-ABL/β2microglobulin after best MRD value and its
relation to relapse.
BCR-ABL level Number of patients Number of relapses (%)
> 10-4 2 1 (50)
< 10-4 2 0
Table 1C. Adverse events during imatinib treatment.
Toxicity Grade I or II, no. (%) Grade III or IV, no. (%)
Nausea/vomiting 6 (86) 1 (14)
Periorbital edema 7 (100) −
Cutaneous rash 1 (14) −
Weakness 5 (71) −
Anemia 2 (28) −
Neutropenia 4 (57) 3 (43)
Thrombocytopenia 4 (57) 3 (43)
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up of 729 days (range 364.8 to 1003.2 days). Only one
(14%) patient, who had been treated with the chemother-
apy induction regimen, relapsed 456 days and died 729
days after the start of imatinib. The median BCR-ABL
value after four weeks of imatinib was 4.1×10-4 (range 1×10-
5- 4.5×10-3). All the patients achieved mCR at least once.
Four out of the seven patients (57%) are still in mCR. The
mCR persisted for a median of 182.4 days (range 91.2-
638.4 days). All of the five patients with persisting mCR
are still in CR as is one of the two patients with short
mCR. At a median of 319.2 days (range 91.2 to 364.8 days)
from molecular relapse (mRel), three (75%) out of four
patients maintained the hCR (Figure 1C). An increase of
MRD were observed in four (67%) of the seven patients.
The magnitude of increase is shown in Figure 1D. The
BCR-ABL/β2microglobulin ratio after the best MRD value
and its relation to relapse are shown in Table 1B. Adverse
events are shown in Table 1C. In accordance with previous
reports of low hepatic toxicity of imatinib treatment,4,7
none of our patients developed liver function abnormali-
ties during imatinib maintenance. Of note, only one
patient had presented severe hepatic toxicity (WHO grade
IV), on day +20 of the induction chemotherapy, which was
withdrawn.
This is the first reported homogenous series in which
imatinib alone was used successfully as maintenance treat-
ment. Our data show 2-year OS and PFS higher than those
reported in the literature for Ph+ALL patients treated with
either chemotherapy, or allogeneic BMT, or imatinib as sal-
vage treatment (75% versus 15%, 64% and 22%, respec-
tively).1-5,7-9 In agreement with the literature data,3,4,8 we
observed: (i) a longer period of mCR in long-term respon-
ders, with BCR-ABL levels either lower than the 10-2
threshold after four weeks of imatinib, or lower than 10-4
after the best MRD value; (ii) a rapid increase of BCR-ABL
level of more than 2 log in the only patient who relapsed.
Because of the limited sample size and low relapse rate, we
could not identify a threshold predictive of good response
or of imminent relapse. 
Similarly, we could not correlate the additional cytoge-
netic abnormalities with the clinical outcome of the
patients. In contrast with previously reported data,3,10 mRel
was not invariably associated with hRel in our patients,
probably, due either to the different disease status of the
patients (first CR versus relapsed/refractory), or to the
mechanism of action of imatinib, more specific than the
graft-versus-leukemia effect, at least in some cases, or to
the higher dose of imatinib administered (800 mg vs 600
mg/daily). Recently, a dose increase of imatinib has been
demonstrated to induce higher rates of major cytogenetic
remission and mCR in chronic myeloied leukemia,11 and to
restore the mCR state in Ph+ALL patients who have had a
molecular relapse either after allogeneic BMT or during
imatinib as salvage treatment.12,13
Issues that need to be addressed include the optimal
duration of treatment, whether imatinib may replace or
support chemotherapy and whether such strict MRD mon-
itoring may help to identify which patients could delay or
avoid BMT, especially in the case of unavailability of a sib-
ling donor.
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